LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that the company submitted two Investigational New Drug Applications (INDs) with the U.S. Food and Drug Administration (FDA) on December 23rd. The INDs signify the company’s intentions to begin clinical investigation (human trials) for:
